Sinopep's oligonucleotide CRDMO platform, situated in Hangzhou Biopharma Town, which boasts a highly qualified research team, with more than half of its members holding master's degrees or higher. The platform has achieved significant milestones in oligonucleotide development, including the successful synthesis of various types of oligos such as ASO, SiRNA, and PMO. Additionally, the platform has collaborated with international companies to produce the first generic drug of oligonucleotides, marking a groundbreaking achievement.